BIOMAT Database Logo BIOMAT Database Logo

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. 1991

H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
1st Department of Medicine and Medical Oncology, Whilhelminenspital, Vienna, Austria.

The present trial was designed to evaluate whether interferon (IFN) combined with standard induction chemotherapy and/or interferon remission maintenance treatment improve treatment results in patients with multiple myeloma. Up to now 89 patients have received IFN plus vincristine/melphalan/cyclophosphamide/prednisolone (VMCP) as induction therapy, and 86 conventional VMCP. The proportion of patients with progressive disease was significantly lower (P less than 0.005) under IFN + VMCP as compared to the VMCP treatment group. Survival times were significantly longer (P less than 0.02) after IFN + VMCP induction therapy than after VMCP alone. In the second phase of this investigation, 33 progression-free myeloma patients were assigned to receive IFN as maintenance therapy, and 41 patients served as untreated controls. Patients maintained with IFN showed a tendency towards increased progression-free survival. Haematological side effects were observed significantly more often in patients receiving IFN, with more severe haematological toxicity in patients on the combined IFN + VMCP regimen and an increased number of patients with mild haematological toxicity in the group maintained with IFN. Other side effects, such as fever and fatigue, remained within tolerable limits. In conclusion, the preliminary results of this current clinical trial indicate significant advantages of combined IFN + VMCP induction treatment in terms of reduced disease progression and prolonged survival and possible benefits of IFN maintenance therapy in patients with multiple myeloma.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females

Related Publications

H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
October 1995, Israel journal of medical sciences,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
May 1990, The New England journal of medicine,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
December 2001, The New England journal of medicine,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
August 1993, Polskie Archiwum Medycyny Wewnetrznej,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
September 1986, European journal of cancer & clinical oncology,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
February 1996, Leukemia & lymphoma,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
April 1989, Journal of biological response modifiers,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol.
January 1988, Cancer treatment reviews,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Maintenance therapy with interferon alfa 2b in Hodgkin's disease.
August 1998, Leukemia & lymphoma,
H Ludwig, and A M Cohen, and H Huber, and D Nachbaur, and W F Jungi, and H Senn, and P Günczler, and J Schüller, and S Eckhardt, and H L Seewann
Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
March 2005, World journal of gastroenterology,
Copied contents to your clipboard!